The Geiger lab
T cells are key players in the immune system with the ability to detect and eliminate infected cells and tumors. We study molecular regulations underlying T cell activation and anti-tumor activity. For this, we use a wide range of technologies including mass spectrometry-based proteomics, functional genomics, mouse models and microfluidics-based systems. Our projects aim to provide detailed insights into T cell functionality that can be translated into the clinic to improve anti-cancer immunotherapies.
Quantitative Molecular Analysis of the T cell Response
To explore molecular mechanisms underlying the T cell response, we use quantitative systems approaches including mass spectrometry-based proteomics, RNA-Seq, ATAC-Seq as well as several targeted approaches.
Immune Response to Liver Cancer
We are interested in the immune response to liver cancer. T cells that infiltrate liver tumors are often exhausted and do not work properly. To potentially increase their functionality, we study the underlying regulations by systematically analyzing tumor-infiltrating T cells with high-resolution mass spectrometry and functional assays.
Rapid Identification of T cell Receptors that recognize Tumor Antigens
We develop workflows to efficiently isolate T cells that recognize liver tumor antigens. Tumor-reactive T cells can be grown to large numbers and used for adoptive T cell therapies, a highly personalized form of cancer therapy. In collaboration with the research group of Andrew deMello (ETH Zürich), we use droplet-based microfluidics systems to manipulate and analyze single T cells in a high-throughput format.
We use droplet-based microfluidics devices that are developped in the laboratory of Professor deMello.
We welcome all applications from individuals who are passionate about applying new technologies to studying the immune response to tumors. Please contact Roger with your CV and a cover letter.